All-in-one centrifugal microfluidic device for size-selective circulating tumor cell isolation with high purity.

Citation data:

Analytical chemistry, ISSN: 1520-6882, Vol: 86, Issue: 22, Page: 11349-56

Publication Year:
2014
Usage 103
Abstract Views 95
Link-outs 8
Captures 13
Readers 13
Citations 41
Citation Indexes 41
Repository URL:
http://scholarworks.unist.ac.kr/handle/201301/9682
PMID:
25317565
DOI:
10.1021/ac5035049
Author(s):
Lee, Ada; Park, Juhee; Lim, Minji; Sunkara, Vijaya; Kim, Shine Young; Kim, Gwang Ha; Kim, Mi-Hyun; Cho, Yoon-Kyoung
Publisher(s):
American Chemical Society (ACS); AMER CHEMICAL SOC
Tags:
Chemistry; A-DISC; ISOLATION PLATFORM; CANCER-PATIENTS; WHOLE-BLOOD; LAB; ENUMERATION; ENRICHMENT; CAPTURE; FILTER; CHIP
article description
Circulating tumor cells (CTCs) have gained increasing attention owing to their roles in cancer recurrence and progression. Due to the rarity of CTCs in the bloodstream, an enrichment process is essential for effective target cell characterization. However, in a typical pressure-driven microfluidic system, the enrichment process generally requires complicated equipment and long processing times. Furthermore, the commonly used immunoaffinity-based positive selection method is limited, as its recovery rate relies on EpCAM expression of target CTCs, which shows heterogeneity among cell types. Here, we propose a centrifugal-force-based size-selective CTC isolation platform that can isolate and enumerate CTCs from whole blood within 30 s with high purity. The device was validated using the MCF-7 breast cancer cell line spiked in phosphate-buffered saline and whole blood, and an average capture efficiency of 61% was achieved, which is typical for size-based filtration. The capture efficiency for whole blood samples varied from 44% to 84% under various flow conditions and dilution factors. Under the optimized operating conditions, a few hundred white blood cells per 1 mL of whole blood were captured, representing a 20-fold decrease compared to those obtained using a commercialized size-based CTC isolation device. In clinical validation, normalized CTC counts varied from 10 to 60 per 7.5 mL of blood from gastric and lung cancer patients, yielding a detection rate of 50% and 38%, respectively. Overall, our CTC isolation device enables rapid and label-free isolation of CTCs with high purity, which should greatly improve downstream molecular analyses of captured CTCs.